



Office of the Secretary

UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

May 7, 2012

Peter J. Brann
Brann & Isaacson
184 Main Street, 4th Floor
Lewiston, Maine 04243

Re: *Proposed Acquisition by MaineHealth of Maine Cardiology Associates and Cardiovascular Consultants of Maine, P.A., FTC File No. 101 0010*

Dear Mr. Brann:

The Commission has conducted an investigation to determine whether the proposed acquisition by MaineHealth of Maine Cardiology Associates and Cardiovascular Consultants of Maine, P.A. may violate Section 7 of the Clayton Act or Section 5 of the Federal Trade Commission Act.

Upon further review of this matter, it now appears that no further action is warranted by the Commission at this time. Accordingly, the investigation has been closed. This action is not to be construed as a determination that a violation may not have occurred, just as the pendency of an investigation should not be construed as a determination that a violation has occurred.

Although the Commission has determined not to take action in this matter, the Commission will continue to monitor the cardiology marketplace in Portland to ensure a competitive environment and to protect the interests of consumers.

By direction of the Commission.

Donald S. Clark
Secretary



Office of the Secretary

UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

May 7, 2012

Patricia M. Wagner
Epstein Becker & Green
1227 25th Street, NW
Suite 700
Washington, D.C. 20037

Re: *Proposed Acquisition by MaineHealth of Maine Cardiology Associates and Cardiovascular Consultants of Maine, P.A., FTC File No. 101 0010*

Dear Ms. Wagner:

The Commission has conducted an investigation to determine whether the proposed acquisition by MaineHealth of Maine Cardiology Associates and Cardiovascular Consultants of Maine, P.A. may violate Section 7 of the Clayton Act or Section 5 of the Federal Trade Commission Act.

Upon further review of this matter, it now appears that no further action is warranted by the Commission at this time. Accordingly, the investigation has been closed. This action is not to be construed as a determination that a violation may not have occurred, just as the pendency of an investigation should not be construed as a determination that a violation has occurred.

Although the Commission has determined not to take action in this matter, the Commission will continue to monitor the cardiology marketplace in Portland to ensure a competitive environment and to protect the interests of consumers.

By direction of the Commission.

Donald S. Clark
Secretary